finance.yahoo.com ·
nuvation bio inc q1 2026 002318752
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedNuvation Bio is a biotech company with a commercial-stage oncology drug. Revenue growth is driven by patient mix shift to TKI-naive patients. The company has a long cash runway and expects a milestone payment. No direct commodity or supply chain impact beyond company-specific operations.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Nuvation Bio Q1 2026 product revenue grew 18% sequentially.
- TKI-naive patients exceeded 50% of new starts.
- Acquired safusitinib rights in Japan.
- Expects $30 million milestone from Eisai upon Iptrozy European approval in 2027.
- Cash runway of $533.7 million.
Iptrozy and safusitinib's price impact is flat in the mid-term, with no material changes expected in 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.